Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Telmisartan
Enalapril
Clonidine
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 65 years
- Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the wash-out period
- Written informed consent
Exclusion Criteria:
- Secondary hypertension
- Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)
- Clinically significant sodium depletion as defined by serum sodium level < 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level > 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level < 3.0 mEq/L
- Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm
- Heart rate < 50 bpm
- Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
- Angina pectoris or myocardial infarction
- Cardiac surgery within the past 3 months prior to start the wash-out period
- Stroke within the past 6 months prior to start the wash-out period
- Renal insufficiency defined as creatininaemia > 2mg/dl
- Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant
- Liver insufficiency, defined as bilirubinaemia > 2mg/dl and AST (aspartate aminotransferase) or ALT (alanine-aminotransferase) > twice the upper normal range
- Clinically significant metabolic and endocrine disease
- Autoimmune disease
- Previous history of angioedema
- Body mass index > 30kg/m2
- Arm circumference > 32 cm
- Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.)
- Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure
- Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial
- Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS)
- Predictable lack of patient co-operation
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Active Comparator
Experimental
Active Comparator
Arm Label
Telmisartan
Enalapril
Telmisartan + clonidine TTS1
Enalapril + clonidine TTS1
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in 24-hours mean systolic blood pressure (SBP) (ABPM - ambulatory blood pressure measurement, 24 hours mean represents the average of 24 hourly mean values)
Secondary Outcome Measures
Comparison of SBP ABPM tracing profile
Changes from baseline in trough cuff (sphygmomanometer) SBP
Smoothness index in comparison with baseline
Number of responders
Number of controlled responders
Incidence of adverse events
Number of patients who withdraw due to adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02177461
Brief Title
Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
Official Title
A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
April 2000 (undefined)
Primary Completion Date
August 2002 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Study to assess the efficacy and tolerability of Telmisartan 40-80 mg once daily compared with enalapril 10-20 mg once daily in elderly patients with arterial hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
374 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Telmisartan
Arm Type
Experimental
Arm Title
Enalapril
Arm Type
Active Comparator
Arm Title
Telmisartan + clonidine TTS1
Arm Type
Experimental
Arm Title
Enalapril + clonidine TTS1
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Enalapril
Intervention Type
Drug
Intervention Name(s)
Clonidine
Primary Outcome Measure Information:
Title
Change from baseline in 24-hours mean systolic blood pressure (SBP) (ABPM - ambulatory blood pressure measurement, 24 hours mean represents the average of 24 hourly mean values)
Time Frame
Baseline and week 8
Secondary Outcome Measure Information:
Title
Comparison of SBP ABPM tracing profile
Time Frame
Week 8 and 24
Title
Changes from baseline in trough cuff (sphygmomanometer) SBP
Time Frame
Baseline, week 8 and 24
Title
Smoothness index in comparison with baseline
Time Frame
Baseline, week 8 and 24
Title
Number of responders
Time Frame
Week 8 and 24
Title
Number of controlled responders
Time Frame
Week 8 and 24
Title
Incidence of adverse events
Time Frame
24 weeks
Title
Number of patients who withdraw due to adverse events
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 65 years
Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the wash-out period
Written informed consent
Exclusion Criteria:
Secondary hypertension
Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)
Clinically significant sodium depletion as defined by serum sodium level < 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level > 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level < 3.0 mEq/L
Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm
Heart rate < 50 bpm
Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
Angina pectoris or myocardial infarction
Cardiac surgery within the past 3 months prior to start the wash-out period
Stroke within the past 6 months prior to start the wash-out period
Renal insufficiency defined as creatininaemia > 2mg/dl
Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant
Liver insufficiency, defined as bilirubinaemia > 2mg/dl and AST (aspartate aminotransferase) or ALT (alanine-aminotransferase) > twice the upper normal range
Clinically significant metabolic and endocrine disease
Autoimmune disease
Previous history of angioedema
Body mass index > 30kg/m2
Arm circumference > 32 cm
Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.)
Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure
Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial
Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS)
Predictable lack of patient co-operation
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.317_U04-1024.pdf
Description
Related Info
Learn more about this trial
Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
We'll reach out to this number within 24 hrs